UNIVERSITÄTS
KLINIKUM
HEIDELBERG

Sektion Stammzelltransplantation:

Jahresbericht 2022



Prof. Dr. Peter Dreger

Klinik Innere Medizin V

Universitätsklinikum Heidelberg

UK HD

Kennzahlen alloHCT

Allogene Transplantationen UKHD

(Erwachsene + Kinder)



Verschiebungen/Anullierungen (ATX)



Indikationen



Indikationen HCT vs CAR



Benchmarking alloHCT

Allogene Transplantationen UKHD

(Spender Erwachsene)



Medianes Patientenalter



2022:

Median: 59J

Range: 21-74

≥70J: 3 Pt.

Non-relapse mortality by period

(pre-COVID19 vs COVID19)



NRM 21/22:

Early death: 7
GVHD: 5
COVID: 1
Sepsis: 1
Mucor: 1
Neuro: 1
Other: 1

Overall survival by period

(pre-COVID19 vs COVID19)



Wissenschaft alloHCT

2019:

EASIX goes global…



PubMed.gov

easix

Search

Advanced Create alert Create RSS

Filters Timeline Sorted by: Most recent Display options

Save Email Send to

29 results Page 1 of 3

Did you mean ***easi*** (844 results)?

1 Cite Share

Comparison of Pretransplant Prediction Models for Non-Relapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.

Acosta-Medina AA, Baranwal A, Johnson IM, Kharfan-Dabaja MA, Murthy H, Palmer JM, Sproat L, Mangaonkar A, Shah MV, Hogan WJ, Litzow MR, Tefferi A, Alkhateeb HB.

Transplant Cell Ther. 2023 Feb 9:S2666-6367(23)01069-2. doi: 10.1016/j.jtct.2023.02.002. Online ahead of print.

PMID: 36773650

We evaluated the log2-**EASIX** scores by quartiles to assess the effect of increasing values on NRM. ...Further studies are important to validate our findings of the role of **EASIX** in predicting NRM in patients with MF or other myeloproliferative neoplasms undergoing al ...

2 Cite Share

EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation.

Sanchez-Escamilla M, Flynn J, Devlin S, Maloy M, Fatmi SA, Tomas AA, Escribano-Serrat S, Ponce D, Sauter CS, Giralt SA, Scordo M, Perales MA.

Bone Marrow Transplant. 2023 Jan 31. doi: 10.1038/s41409-023-01922-8. Online ahead of print.

PMID: 36721042

We hypothesized that **EASIX** calculated at different time points pre- and post- HCT may predict NRM and OS, and that **EASIX** calculated at onset of GVHD may predict response to steroids. ...Our study shows that high **EASIX** scores at various time points pre- and po ...

Page 1

4 Cite Share

Prognostic value of the endothelial activation and stress index in patients w upper tract urothelial cancer undergoing radical nephroureterectomy.

Gu JS, Ryu JW, Yu SH, Chung HS, Hwang JE, Bae WK, Ku JY, Lee CH, Ha HK, Jung SI, Hwang EC, Kwon DD.

Investig Clin Urol. 2022 Nov;63(6):623-630. doi: 10.4111/icu.20220204.

PMID: 36347551 Free PMC article.

The high **EASIX** score group had worse RFS and OS than the low **EASIX** score group (log-rank p=0.001 and p=0.006, respectively). At 5 years, the mean RFS and OS difference between the low and high **EASIX** score groups was 11.1 and 7.35 months, respectively. High ...

5 Cite Share

Statin-based endothelial prophylaxis and outcome after allogeneic stem cell transplantation.

Pabst C, Schreck N, Benner A, Hegenbart U, Schönland S, Radujkovic A, Schmitt M, Müller-Tidow C, Orsatti L, Dreger P, Luft T.

Eur J Clin Invest. 2023 Feb;53(2):e13883. doi: 10.1111/eci.13883. Epub 2022 Oct 11.

PMID: 36199203

Subgroup analyses showed that the NRM benefit was mainly found in patients with an intermediate endothelial activation and stress index (**EASIX**), while relapse risk was not affected. On day 100 post-alloSCT, patients receiving SEP had significantly higher levels of the rate ...

6 Cite Share

High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant.

Baranwal A, Mangaonkar A, Shah MV, Litzow MR, Hogan WJ, Patnaik MM, Alkhateeb HB.

Bone Marrow Transplant. 2022 Dec;57(12):1842-1844. doi: 10.1038/s41409-022-01829-w. Epub 2022 Sep 21.

PMID: 36131003 Free PMC article. No abstract available.

7 Cite Share

Endothelial activation and stress index (EASIX) as a predictive biomarker in small cell lung cancer.

Go SI, Park S, Kang MH, Kim HG, Kang JH, Kim JH, Lee GW.

Cancer Biomark. 2022;35(2):217-225. doi: 10.3233/CBM-220032.

PMID: 36120771

OBJECTIVE: To evaluate the clinical impact of the endothelial activation and stress index (**EASIX**) in SCLC. METHODS: In this retrospective study, the **EASIX** was calculated from measurements of serum lactate dehydrogenase, creatinine, and platelet levels. ...CONCLUSION ...

Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic

European Journal of Clinical Investigation
ESCI
2023;53(2):e13883

Statin-based endothelial prophylaxis and outcome after allogeneic stem cell transplantation

Caroline Pabst[1] | Nicholas Schreck[2] | Axel Benner[2] | Ute Hegenbart[1] | Stefan Schönland[1] | Aleksandar Radujkovic[1] | Michael Schmitt[1] | Carsten Müller-Tidow[1] | Laura Orsatti[3] | Peter Dreger[1] | Thomas Luft[1]







(A)



Leukemia
2023;37(2):465

Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters

Peter-Martin Bruch[1,2], Sascha Dietrich[1,2,3]✉, Herve Finel[3], Ariane Boumendil[3], Hildegard Greinix[4], Thomas Heinicke[5], Wolfgang Bethge[6], Dietrich Beelen[7], Christoph Schmid[8], Hans Martin[9], Luca Castagna[10], Christof Scheid[11], Kerstin Schäfer-Eckart[12], Jörg Bittenbring[13], Jürgen Finke[14], Henrik Sengeloev[15], Mael Heiblig[16], Jan Cornelissen[17], Patrice Chevallier[18], Mohamad Mohty[19], Stephen Robinson[20], Silvia Montoto[21] and Peter Dreger[2]



EBMT cohort:

- N=162
- 57y (20-73)
- CR1 78%
- MAC 54%
- **MAC TBI 33%**

Impact Sektion SZT 2022

(peer-reviewed only, ohne AG Schmitt)

Jahr	Titel	Veröffentlicht in	Gruppe	Journal Impact Faktor 2021	Multiplikator	Publikationspunkte	Autor Med V
2022	Long-term survival in a fraction of patients with metastatic breast cancer who received co	Bone Marrow Transplant	Koautorenschaft	**5.67**	1	5.67	**Dreger**
2022	Humoral and cellular responses after COVID-19 vaccination in anti-CD20 treated lymphor	Blood	Koautorenschaft	**25,48**	1	25,48	**Dreger**
2022	Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Sc	Blood Advances	Letztautorenschaft	**7.64**	8	61.14	**Dreger**
2022	Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without C	Hemasphere	Koautorenschaft	**8,30**	1	8.30	**Dreger**
2022	Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogene	Int J Mol Sci	Erst-/Letztautorenschaft	**6,01**	10	60,10	**Schwarzbich, Luft**
2022	Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allo	Vaccines	Erst-/Letztautorenschaft	**4.96**	10	49.61	**Pabst. Luft**
2022	GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma i	Blood	Letztautorenschaft	**25,48**	8	203,81	**Dreger**
2022	Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic	Bone Marrow Transplant	Koautorenschaft	**5,67**	1	5,67	**Dreger**
2022	EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Co	Front Immunol	Erst-/Letztautorenschaft	**8.79**	10	87.86	**Korell. Luft**
2022	Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/I	Blood Advances	Koautorenschaft	**7,64**	1	7,64	**Fischer, Dreger**
2022	Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic her	Bone Marrow Transplant	Erst-/Letztautorenschaft	**5.67**	10	56.69	**Meissner. Dreger**
2022	Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic	Am J Hematol	Koautorenschaft	**13.27**	1	13.27	**Dreger**
2022	Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in	Haematologica	Koautorenschaft	**5,53**	1	5,53	**Dreger, Schönland**
2022	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in secor	Blood	Koautorenschaft	**25,48**	1	25,48	**Dreger**
2022	Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subs	Mol Syst Biol	Koautorenschaft	**11,15**	1	11,15	**Dreger**
2022	Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative u	Bone Marrow Transplant	Koautorenschaft	**5,67**	1	5,67	**Dreger**
2022	Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamus	Lancet Haematol	Koautorenschaft	**30,15**	1	30.15	**Dreger**
2022	Zahl der Stammzelltransplantationen während der COVID-19-Pandemie	DÄB	Letztautorenschaft	**8,25**	8	66,01	**Dreger**
2022	Proteogenomics refines the molecular classification of chronic lymphocytic leukemia	Nat Comm	Koautorenschaft	**15.41**	1	15.41	**Dreger**
2022	Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRS	Bone Marrow Transplant	Erstautorenschaft	**5.67**	8	45.35	**Dreger**
2022	Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dend	Leukemia	Erst-/Letztautorenschaft	**9,33**	10	93,30	**Bruch, Dreger**
2022	Haploidentical versus matched unrelated donor transplants using post-transplant cycloph	Transplant Cell Ther	Koautorenschaft	**5.61**	1	5.61	**Dreger**
2022	Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematol	Nat Cancer	Koautorenschaft	**23,18**	1	23,18	**Dreger**
2022	Comparison of outcomes for HLA-matched sibling and haplo-identical donors in MDS	Blood Cancer J	Koautorenschaft	**11,04**	1	11,04	**Luft**
2022	Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation	Intensive Care Med	Erst-/Letztautorenschaft	**17.44**	10	174.40	**Korell. Luft**
2022	Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogen	Bone Marrow Transplant	Koautorenschaft	**5,67**	1	5,67	**Radujkovic**
2022	Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international co	Blood	Koautorenschaft	**25,48**	1	25.48	**Radujkovic**
2022	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leuka	Br J Haematol	Erstautorenschaft	**8.62**	8	68.92	**Radujkovic**
2022	Prognostic value of a new clinically-based classification system in patients with CMML und	Bone Marrow Transplant	Koautorenschaft	**5,67**	1	5,67	**Radujkovic**
				343,90		1.203.23	

Kennzahlen

CARTs

CART-Therapien (Indikationen)



Verwendete CARTs

2022 (n=42)





2020-2021 (n=72)



Verwendete CARTs

2022 (n=42)



Liso-cel in DLBCL

d -15

d +15

Benchmarking CART

Strukturprüfung durch den MD gemäß QS-RL ATMP

Anlage II
zum Beschluss über Maßnahmen zur Qualitätssicherung der Anwendung von CAR-T-Zellen bei B-Zell-Neoplasien

Checkliste für das Nachweisverfahren nach § 10 zur Erfüllung von strukturellen Qualitätsanforderungen nach Maßgabe der §§ 3-8

Selbstauskunft der Behandlungseinrichtung

Die Behandlungseinrichtung _____ in _____

erfüllt die

☐ **strukturellen Mindestanforderungen zur Anwendung von CAR-T-Zellen bei B-Zell-Neoplasien.**

Institutionskennzeichen: _____

Standortnummer: _____

Der Medizinische Dienst (MD) ist berechtigt, die Richtigkeit der Angaben der Einrichtungen nach Maßgabe der MD-QK-RL vor Ort zu überprüfen. Neben dem Betreten von Räumen des Krankenhauses zu den üblichen Geschäfts- und Betriebszeiten ist der MD insbesondere befugt, die zur Erfüllung des Kontrollauftrags erforderlichen Unterlagen einzusehen (§ 9 Abs. 4 AT MD-QK-RL). Das Krankenhaus hat die erforderlichen Auskünfte zu erteilen (§ 9 Abs. 6 AT MD-QK-RL).

Bericht über die Kontrolle der Einhaltung der Qualitätsanforderungen gemäß Anlage I der Richtlinie zu Anforderungen an die Qualität der Anwendung von Arzneimitteln für neuartige Therapien CAR-T-Zellen bei B-Zell-Neoplasien bei erwachsenen Patientinnen und Patienten

Kontrolliertes Krankenhaus: Universitätsklinikum Heidelberg
Institutionskennzeichen: 260820466

Kontrollierter Standort: Campus Neuenheimer Feld
Standortnummer: 771700000

Datum Kontrollbericht: 10.01.2023

Kontrollergebnis

Anforderungen erfüllt

Die Mindestanforderungen sind plausibel erfüllt.

Germany: Qualified CART centres (Feb 2023)

Total (43)



blood

BLOOD 2022, March 24 online

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Wolfgang Andreas Bethge,[1] Peter Martus,[2] Michael Schmitt,[3] Udo Holtick,[4] Marion Subklewe,[5] Bastian von Tresckow,[6] Francis Ayuk Eva Marie Wagner-Drouet,[8] Gerald G. Wulf,[9] Reinhard Marks,[10] Olaf Penack,[11] Ulf Schnetzke,[12] Christian Koenecke,[13] Malte von Bonin,[14] Matthias Stelljes,[15] Bertram Glass,[16] Claudia D. Baldus,[17] Vladan Vucinic,[18] Dimitrios Mougiakakos,[19] Max Topp, Matthia Alexander Fante,[21] Roland Schroers,[22] Lale Bayir,[13] Peter Borchmann,[4] Veit Buecklein,[5] J Hasenkamp,[9] Christine Hanoun,[6] Simone Thomas,[21] Dietrich W. Beelen,[6] Claudia Lengerke,[1] Nicolaus Kroeger,[7] and Peter Dreger[3] on behalf of the German Lymphoma Alliance (GLA) and the German Stem Cell Transplantation Registry (DRST)

N=356, Follow-up 12 months



German Lymphoma Alliance

DRST Deutsches Register für Stammzelltransplantationen

BMT
2023;58(2):229

Peter Dreger[1], Udo Holtick[2], Marion Subklewe[3], Bastian von Tresckow[4], Francis Ayuk[5], Eva Wagner[6], Gerald Wulf[7], Reinhardt Marks[8], Olaf Penack[9], Ulf Schnetzke[10], Christian Koenecke[11], Malte von Bonin[12], Matthias Stelljes[13], Bertram Glass[14], Claudia D. Baldus[15], Vladan Vucinic[16], Dimitrios Mougiakakos[17], Max Topp[18], Roland Schroers[19], Daniel Wolff[20], Simone Thomas[20,21], Nicolaus Kröger[5], Wolfgang A. Bethge[22], on behalf of the German Lymphoma Alliance (GLA)*the German Stem Cell Transplantation Registry

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience





Non-relapse mortality by product

(Heidelberg)



COD:

Sepsis: 5
Viral: 2
Fungal: 1
Multi-organ fail: 1
LAE: 1
Neuro: 1
Unknown: 1

Idecel: Overall survival

(Heidelberg, n=23)



JCO
2023, Feb 8

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

Yucai Wang, MD, PhD[1]; Preetesh Jain, MBBS, MD, DM, PhD[2]; Frederick L. Locke, MD[3]; Matthew J. Maurer, DMSc[1]; Matthew J. Frank, MD, PhD[4]; Javier L. Munoz, MD, MS, MBA[5]; Saurabh Dahiya, MBBS[6]; Amer M. Beitinjaneh, MD[7]; Miriam T. Jacobs, MD[8]; Joseph P. Mcguirk, MD, PhD[9]; Julie M. Vose, MD[10]; Andre Goy, MD[11]; Charalambos Andreadis, MD, MSCE[12]; Brian T. Hill, MD, PhD[13]; Kathleen A. Dorritie, MD[14]; Olalekan O. Oluwole, MBBS, MPH[15]; Abhinav Deol, MD[16]; Jonas Paludo, MD[1]; Bijal Shah, MD[3]; Trent Wang, DO, MPH[7]; Rahul Banerjee, MD[12]; David B. Miklos, MD[4]; Aaron P. Rapoport, MD[6]; Lazaros Lekakis, MD[7]; Armin Ghobadi, MD[8]; Sattva S. Neelapu, MD[2]; Yi Lin, MD, PhD[1]; Michael L. Wang, MD[2]; and Michael D. Jain, MD, PhD[3]

N=167; med FU 14mo; 12 mo PFS 59%





MCL: OS after BTKi failure
(Martin P et al, Blood 2016)

Brexucel UKHD

(2020-2023, n=8, med fu 8mo)

- PFS: 4/8 (+537, +250, +90, +39)
- Relapse: 2/8 (+311, +91)
- NRM: 2/8 (+292 infection, +90 LAE)

German RWA and AbD under preparation

Wissenschaft CARTs

INTEGRATE-ATMP

Integrierte Versorgung

Sektorenübergreifende Versorgung
Qualitätsgesicherte, strukturierte Vor- und Nachsorge

Neue Therapien

Alters- und Fachabteilungsübergreifende ATMPs

Telemedizin

Weiterentwicklung bestehender Campus-Lösungen zur Erfassung von "Digital Health Outcomes"

Empowerment

Patient Involvement
Wissenstransfer an externe Zentren



Gentherapeutika

- Onasemogen Abeparvovec (Zolgensma®) - spinale Muskelatrophie
- Betibeglogene Autotemcel (Zynteglo®) - Beta-Thalassämie
- Autologous CD34+ cells transduced to express ADA (Strimvelis®) - ADA-SCID
- CAR T-Zellen (Kymriah®/ Yescarta®)

Register

Krankheitsübergreifendes und Industrie-unabhängiges ATMP-Register

Arzneimittelsicherheit

Therapiepfade

Standardisierte Überwachung und Dokumentation des Therapieerfolges und von UAW

Erstattungsmodelle

Validierte Vergütungsmodelle für die qualifizierte Nachsorge der Patienten

UK HD

Sektion SCT: Trial activity

Study	Study type	Topic	PI HD	Sponsor	n
INTEGRATE	Versorgungsf.	ATMP Lymphom	Müller-T.	UKHD	9
HD-CAR-1	Phase-1/2	ALL, CLL, NHL	Schmitt	UKHD	37
DALY-2	Phase-3	Zamtocel (LBCL 2L)	Dreger	Miltenyi	4
PET-MRT	Phase-2	PET CAR LBCL	Schlemmer	DKFZ	6
CARMEN	Phase-2	Brexucel MCL 1L	Dreger	LMU	-
ZUMA-25	Phase-2	Axicel BL, RT, WM, HCL	Dreger	Gilead	-
CHARLY	Phase-2	NHL haplo	Dietrich	UKHD	7
VIAL	Phase-2	VV post allo AML	Luft	AbbVie	1
IRENE	RCT non-AMG	Sport GVHD outc.	Kühl	NCT	21

HEIDELBERG UNIVERSITY HOSPITAL

DGHO DEUTSCHE GESELLSCHAFT FÜR HÄMATOLOGIE UND MEDIZINISCHE ONKOLOGIE
ÖGHO Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie
SSMO SSOM SGMO
SGH+SSH

JAHRESTAGUNG
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie
www.jahrestagung-haematologie-onkologie.com

2022 WIEN
7.–10. OKTOBER

V146 CD19-gerichtete chimäre Antigen-Rezeptor (CAR) T-Zellen der dritten Generation für rezidivierte oder refraktäre CLL – Update der laufenden akademischen Phase 1/2-Studie HD-CAR-1

P. Derigs, A. Kunz, P. Dreger, A. Schmitt, M.-L. Schubert, M. Brüggemann, H. Bernhard, G. Kobbe, A. Lindemann, M. Rummel, L. Wang, B. Michels, P. Waldhoff, F. Korell, S. Laier, A.D Ho, C. Müller-Tidow, M. Schmitt

Medizinische Klinik V (Hämatologie, Onkologie, Rheumatologie)
Universitätsklinikum Heidelberg

UK HD

Outcome (Update Feb 2023)

#	Alter	Vortherapien	TP53 abn	Erkrankungs-status bei LD	DL	Best response	Current status (days after dosing)
1	54M	FC, BR, … (n = 10)	+	PD MRD 0,5%	I	**Near PR (-46%)** **MRD 0.035%**	**PD d 184** **Died d 914**
2	60M	FCR, BR, … (n = 6)	+	SD MRD 16%	II	**SD** **MRD 0.04%**	**PD d 89** **Died d 309**
3	62M	BR, Ibr, … (n = 5)	+	CR MRD 3,8%	V	**CR** **MRD-**	**CR MRD- d 650+**
4	64M	BR, Ibr, … (n = 4)	-	CR MRD 0,01%	V	**CR** **MRD-**	**REL d 281** **Alive d 629+**
5	68M	FCR, BR, … (n = 5)	+	PR MRD 21%	V	**CR** **MRD 0.02%**	**CR d 196; REL d 367;** **Died d 423**
6	63	Ibr, VenR … (n = 2)	+	CR MRD 0,4%	V	**CR** **MRD-**	**CR MRD- d 275+**
7	56	FC, FCM, … (n = 10)	+	PR	V	**CR** **MRD-**	**REL d 117** **Alive d 420+**

Thank you for being one of our top authors - Nachrich...

Datei Nachricht Hilfe Was möchten Sie tun?

BA

Blood Advances <update@author.email.elsevier.com> Dreger, Peter 21.07.2022

Thank you for being one of our top authors

Sie haben diese Nachricht am 21.07.2022 12:01 weitergeleitet.

blood advances®

Thank you for being one of our top authors

Dear Dr. Dreger,



You may have heard the announcement that the new *Blood Advances* Impact Factor is 7.637*, which ranks the journal in the top 20% of hematology journals. We are very pleased to inform you that your article is one of the most highly cited in the journal and has thus made a direct contribution to this high ranking.

CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: An intent-to-treat comparison received **10** citations** since publication

On behalf of the *Blood Advances* Editorial Board, we thank you and your co-authors for selecting our journal to publish your article. As a journal with a rapidly growing reputation, impactful papers like yours are vitally important. We hope you will share this news and our thanks with your fellow authors.

Vielen Dank und alles Gute, lieber Aleks…

…willkommen im allo-Team, liebe Caroline!

Danke!

„von Dusch“
M Lommatzsch
A Dugimont
...und das Team!

Station
L Claßen
S Alptekin
K Dimitriou
M Janssen
E Lasitschka
M von Lucadou
AL Müller
C Ody
C Pixberg
C Salbach
V Schmidt
A Martin

M Boxberger
E Schulze Schleithoff

Koordination
P Stadtherr
I Opitz
A Smeykal

Ambulanz
U Hegenbart
S Schönland
A Radujkovic
C Pabst
ML Schubert
L Simons
K Farid
I Haberbosch
J Fuhrmann
A Tariq

CART
M Schmitt
A Schmitt
ML Schubert

ECP & Leukapherese
A Schmitt
S Sauer
& Team

Case Manager & CART Koord.
A Bondong
M Wegner

Myelom CARTs
MS Raab
S Sauer
B Kopp

ZPM
H Giller
B Just
& Team

Labor
T Luft
M Hess
A Radujkovic

Psychologie
D Tönnessen

Sucheinheit
H Tran
K Nerbel
& Team

A QM
B Beck

EBMT-Reporting
M Fischer

Sozialdienst
G Calahorro
G Daiß
S Sontowski

Studienzentrale
J Klemmer
& Team

I.O. und andere Affairs
M Geiss
N Giesen

Anleitung
T Luft
P Dreger

Klinikleitung
C Müller-Tidow